Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Reata Pharma
(NQ:
RETA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 25, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Reata Pharma
< Previous
1
2
3
4
5
6
7
8
Next >
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
December 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
60 Biggest Movers From Yesterday
December 07, 2021
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 200.4% to close at $15.05 on Monday after the company announced the commencement of a formal process to explore...
Via
Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Exposures
Product Safety
FDA Raises Concerns On Reata's Kidney Disease Drug Data; Shares Plunge
December 06, 2021
Reata Pharmaceuticals Inc (NASDAQ: RETA) shares are trading lower during the market trading session after the FDA released briefing documents ahead of the Advisory...
Via
Benzinga
Exposures
Product Safety
Reata Pharma Stock Dives 40% As FDA Reviewers Waffle On Kidney Disease Drug
December 06, 2021
FDA experts are set to debate the drug's merits and risks on Wednesday.
Via
Investor's Business Daily
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Intraday Session
December 06, 2021
Gainers Adicet Bio (NASDAQ:ACET) shares i...
Via
Benzinga
36 Stocks Moving In Monday's Mid-Day Session
December 06, 2021
Gainers Del Taco Restaurants, Inc. (NASDAQ: TACO) shares jumped 64.6% to $12.40. Jack In The Box Inc (NASDAQ: JACK) agreed to acquire Del Taco Restaurants for $12.51 per share...
Via
Benzinga
Mid-Morning Market Update: Markets Mostly Higher; Science Applications International Posts Upbeat Earnings
December 06, 2021
Following the market opening Monday, the Dow traded up 1.35% to 35,048.01 while the NASDAQ fell 0.17% to 15,059.43. The S&P also rose, gaining 0.59% to 4,565.21. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
December 02, 2021
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
November 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack...
Via
Benzinga
Reata Pharmaceuticals, inc (RETA) Q3 2021 Earnings Call Transcript
November 08, 2021
RETA earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Reata Pharmaceuticals's Return On Capital Employed Overview
November 08, 2021
According to Benzinga Pro data, during Q3, Reata Pharmaceuticals (NASDAQ:RETA) posted sales of $7.39 million. Earnings were up 3.38%, but Reata Pharmaceuticals still reported an...
Via
Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
Reata Pharmaceuticals: Q3 Earnings Insights
November 08, 2021
Reata Pharmaceuticals (NASDAQ:RETA) reported its Q3 earnings results on Monday, November 8, 2021 at 08:00 AM. Here's what investors need to know about the announcement...
Via
Benzinga
Earnings Scheduled For November 8, 2021
November 08, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...
Via
Benzinga
A Preview Of Reata Pharmaceuticals's Earnings
November 05, 2021
Reata Pharmaceuticals (NASDAQ:RETA) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
October 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc...
Via
Benzinga
Reata Pharmaceuticals's Return on Invested Capital Overview
September 17, 2021
Benzinga Pro data, Reata Pharmaceuticals (NASDAQ:RETA) reported Q2 sales of $2.22 million. Earnings fell to a loss of $60.13 million, resulting in a 9.5% decrease from last...
Via
Benzinga
Why Reata Pharmaceuticals Stock Is Diving Today Despite Q2 Beats
August 10, 2021
The FDA pours cold water on the company's better-than-expected quarter.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Product Safety
85 Biggest Movers From Yesterday
August 11, 2021
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX...
Via
Benzinga
54 Stocks Moving In Tuesday's Mid-Day Session
August 10, 2021
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy...
Via
Benzinga
Reata's Stock Plunges After FDA Identifies Review Issues With Bardoxolone Methyl US Application
August 10, 2021
Reata Pharmaceuticals Inc (NASDAQ: RETA) issued an update regarding its Bardoxolone Methyl application for chronic kidney disease (CKD) caused by Alport syndrome....
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 10, 2021
Gainers Arcturus Therapeutics (NASDAQ:ARCT) shares rose 25.93% to $60.75 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5...
Via
Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
August 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
Exposures
COVID-19
28 Stocks Moving in Tuesday's Pre-Market Session
August 10, 2021
Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares rose 38.6% to $66.88 in pre-market trading after the company reported better-than-expected Q2 earnings and also...
Via
Benzinga
Reata Pharmaceuticals, inc (RETA) Q2 2021 Earnings Call Transcript
August 10, 2021
RETA earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
8 Stocks Moving In Monday's After-Hours Session
August 09, 2021
Gainers Kansas City Southern (NYSE: KSU) shares are trading higher following a report suggesting Canadian Pacific plans a new higher bid for the company, near $300 per share....
Via
Benzinga
Reata Pharmaceuticals: Q2 Earnings Insights
August 09, 2021
Shares of Reata Pharmaceuticals (NASDAQ:RETA) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 7.32%...
Via
Benzinga
Earnings Scheduled For August 9, 2021
August 09, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.